人胰岛素突变体GIRR的分离纯化及性质研究

构建人胰岛素原突变体GIRR(A2 1Asn→Gly,B1 7Leu→Ile ,B31Arg ,B32Arg)基因的原核融合表达载体并进行表达和纯化 ,进一步对其性质进行研究。将人胰岛素原突变体基因重组到pTXB1融合表达载体上 ,在E .coliBL2 1 (DE3)中得到高效表达。表达产物经几丁质亲和柱层析分离以及胰蛋白酶和羧肽酶B的酶促转化等步骤 ,得到纯的人胰岛素突变体GIRR ,其纯度经HPLC鉴定达到 95 % ,氨基酸组成和设计相符 ,其受体结合活性是猪胰岛素的 1 0 5 % ,生物活性为 2 6.8IU/mg。其血浆半衰期为 2 0分钟 ,比标准猪胰岛素提高 3倍多。结果提示本突变体具有更长的半衰期 ,为长效胰岛素的制备提供了新的思路。     

人胰岛素突变体的分离纯化及性质研究

将人胰岛素原突变体(A4Glu→Leu)基因重组到pBV220表达载体上,在E.coli系统中得到高效表达,表达产物经SephadexG-50柱层析分离以及胰蛋白酶和羧肽酶B的酶促转化等步骤,可得到纯的人胰岛素突变体(A4Glu→Leu),其氨基酸组成与预期值相符,其受体结合活性及生物活性与标准猪胰岛素的基本相同.     

重组人胰高血糖素样肽-1突变体的分离纯化及活性分析

对基因工程构建的含人胰高血糖素样肽1(hGLP1)突变体的工程菌株进行诱导表达,分离纯化N末端第二位突变的2GlyhGLP1突变体.IPTG诱导4h,收获的菌体经超声破碎后,裂解液用GlutathioneSepharose4B亲和层析纯化GST2GlyhGLP1融合蛋白,经CNBr裂解、SephadexG25柱脱盐、QAESepharoseFF阴离子交换柱层析和RPC18柱脱盐,得到纯度大于98%的重组2GlyhGLP1.Western印迹分析证实,该突变体可被特异性hGLP1抗体所识别.生物学活性分析表明,2GlyhGLP1具有明显的降血糖活性和促胰岛素分泌活性(P<0.001).     

抗凝活性肽RGD226基因构建、表达、产物纯化及活性分析

通过PCR法 ,将来源于蛇毒蛋白质eristostatin中的一段含有RGD(Arg Gly Asp)序列的十三肽(SRVARGDWNDDYS)的基因 ,以一个无胰岛素活性但保留天然免疫原性的胰岛素原突变体(PJG4 0 1)基因为模板 ,置换其B2 8和A1位之间的连接肽基因 ,构建成了能展示RGD功能序列的人源化分子 (RGD2 2 6 )的基因 .通过该基因在大肠杆菌中的表达、产物分离纯化 ,得到高纯度RGD2 2 6 .该RGD肽对由ADP诱导的体外人血小板聚集的半抑制浓度IC50 为 2 2 3μmol L .其胰岛素免疫活性是PJG4 0 1的 15 1% ,提示其在一定程度上保留了胰岛素原的免疫原性 .其受体结合活性不到PJG4 0 1的 0 1% ,说明其胰岛素的生物活性基本丧失 .动物实验证实 ,RGD2 2 6在延长小鼠出血时间上具有较明显的作用     

A7—B7二硫键缺失对胰岛素原重折叠及结构的影响

为研究A7 B7二硫键在胰岛素原结构和折叠中的作用 ,构建了A7 B7二硫键缺失的胰岛素原突变体 ,研究了其与野生型胰岛素原在体外重折叠产率、自由巯基氧化速度、CD谱、受体及抗体结合活性 ,以及对胰蛋白酶酶切敏感性的差别。结果表明 ,A7 B7二硫键缺失可导致胰岛素原α 螺旋明显减少以及对胰蛋白酶的酶切敏感性显著增加 ,其对胰岛素原结构的影响主要导致了受体结合活性的大幅度降低。突变体在体外重折叠 1h后巯基氧化速率较野生型明显减慢 ,但其最终折叠产率与野生型相当。由此提出一个胰岛素原折叠的可能途径 ,即A链链内二硫键最先形成 ,然后是两对链间二硫键。且A2 0 B19二硫键比A7 B7二硫键很可能先形成 ,在折叠中更重要。     

[A6-Ala,A11-Ala]-人胰岛素突变体的构建及其生物活性

利用 PCR技术 ,将胰岛素原基因中 A6和 A1 1的 Cys序列突变成 Ala序列 ,以去除 A链的链内二硫键 .突变基因连接到质粒 p BV2 2 0 ,构建了表达质粒 p JG40 3,并且在大肠肝菌中得到表达 .经过 Sephadex G- 50层析可得到纯化的突变人胰岛素原 ( Mut- HPI- Ala) .纯化产物用胰蛋白酶和羧肽酶处理 ,并经 Resource Q阴离子交换柱层析可进一步获得纯化的突变人胰岛素 ( Mut- HI- Ala) .Native- PAGE分析表明 Mut- HI- Ala的结构松散 .Mut- HPI- Ala的放射免疫活性和胰岛素受体结合活性是非突变人胰岛素原 ( Met- HPI)的 4.6%和 2 .4% .Mut- HI- Ala的放射免疫活性和胰岛素受体结合活性是非突变人胰岛素 ( Met- HI)的 4.3%和 4.6% .实验结果表明 ,胰岛素 A链内的二硫键对胰岛素的生物活性起着重要的作用     

人胰岛素原类似物(BKRA)基因的合成与表达

为了利用基因工程生产胰岛素,按照已知的人胰岛素Ａ、Ｂ链氨基酸序列和大肠杆菌偏爱的氨基酸密码子设计并合成了人胰岛素原类似物（ＢＫＲＡ）基因,其中以赖（Ｋ）－精（Ｒ）二肽编码区取代人胰岛素原Ｃ肽编码区．为了避免其编码蛋白在大肠杆菌中表达时被降解,通过人工接头将２个ＢＫＲＡ基因串联起来,接头部分氨基酸序列为Ａｒｇ－Ａｒｇ－Ａｓｎ－Ｓｅｒ．将串联的ＢＫＲＡ基因克隆到表达载体ｐＥＴ－２８ａ（＋）,实现了在大肠杆菌中的融合表达,表达产物以包含体形式存在,约占细菌总蛋白２４％．表达产物氨基末端具有六组氨酸肽段,以ＨｉＴｒａｐ凝胶进行亲和层析,一步纯化可达纯度９５％以上．放射免疫测定表明,纯化的融合蛋白具有胰岛素抗原活性．表明已构建成人胰岛素原类似物的高效表达菌株     

霍乱毒素B亚单位与胰岛素原融合基因的克隆、表达及重组蛋白特性分析

构建了霍乱毒素B亚单位 (CholeratoxinBsubunit,CTB)与胰岛素原 (Proinsulin)的融合基因CTB -PROIN ,将该融合基因克隆到大肠杆菌表达载体pET 30a(+)中 ,获得重组质粒pETCPI,并将该质粒转入大肠杆菌菌株BL21(DE3)中 ;重组菌株经IPTG诱导后 ,其表达产物经过 15 %SDS PAGE分析表明该菌株可以表达融合蛋白 ,其分子量约为 21.6kD ,且主要以包涵体形式存在 ,约占全菌蛋白的 25%。含CTB-PROIN重组蛋白的包涵体经过变性和复性后 ,CTB-PROIN可以在体外自组装成五聚体结构。Westernblotting分析结果表明重组CTB PROIN蛋白可分别被霍乱毒素的抗体和胰岛素的抗体识别 ,说明该蛋白具有霍乱毒素和胰岛素的双重抗原性。同时在体外 ,CTB PROIN蛋白可与神经节苷脂GM1(monosialoganglioside)特异性结合 ,表明了该融合蛋白在体外具有生物活性。这些研究结果为利用原核生物表达系统研制廉价、高效的I型糖尿病口服疫苗奠定了基础。     

Met-Lys-双C肽人胰岛素原基因的构建表达及分离纯化

应用 Ｐ Ｃ Ｒ 定点突变方法构建编码 Ｍ ｅｔ Ｌｙｓ 双 Ｃ 肽人胰岛素原基因,并在大肠杆菌中以包含体方式获得表达 表达产物经还原、重组、 Ｓｅｐｈａｄｅｘ Ｇ ７５ 分离纯化,获得 Ｍ ｅｔ Ｌｙｓ 双 Ｃ 肽人胰岛素原,经胰蛋白酶与羧肽酶 Ｂ的酶解, Ｒｅｓｏｕｒｃｅ Ｔ Ｍ Ｑ 阴离子交换柱层析分离制备得人胰岛素,其放免活性、受体结合活性均与猪胰岛素相同      

基因工程人胰岛素原和胰岛素的分离纯化及性质研究

携带pWR 590-BCA4质粒的大肠杆菌经发酵培养,提取出人胰岛素原融合蛋白。该融合蛋白经BrCN降解,氧化磺化及QAE-Sepha-dex A-25和Sephadex G-50分离所得到的磺化胰岛素原,经折叠和分离得到了人胰岛素原(HPI)。HPI 再经酶切转化为人胰岛索(HI)和C-肽,HI 的得率为5 m8/L,并获得了HI 的晶体。HPI 和HI 的氨基酸组成、N-端顺序和C-末端分析均与预期值相符。HI 的RIA 活性为猪胰岛素的99%,整体活性为26～27U/mg。     

B27K—去B链C端三肽胰岛素的制备、生物活力与自聚合性质

液相合成五肽Gly Phe Phe Tyr Lys(Boc)Obut,与B链C端去八肽胰岛素酶促缩合得到B2 7K 去B链C端三肽胰岛素(B2 7K DTrI,B2 7K destripeptideinsulin)。用小鼠惊厥法和小鼠降血糖法测得B2 7K DTrI的整体生物活力为标准胰岛素的 80 % ,B2 7K DTrI与人胎盘细胞膜胰岛素受体结合能力为标准胰岛素的 ( 12 5± 13 ) %。用凝胶过滤法证明B2 7K DTrI自聚合性质降低 ,具有与去B链C端五肽胰岛素相同的单体性质。在B2 7K DtrI结构中 ,B2 7T被K取代 ,其优点是在酵母中表达其前体后 ,可以很方便地通过胰蛋白酶水解获得     

Protein engineering of insulin: Two novel fast-acting insulins [B16Ala]insulin and [B26Ala]insulin

Blood glucose lowering assay proved that [B16Ala]insulin and [B26Ala]insulin exhibit potency of acute blood glucose lowering in normal pigs, which demonstrates that they are fast- acting insulin. Single-chain precursor of [B16Ala]insulin and [B26Ala]insulin is [B16Ala]PIP and [B26Ala]PIP, respectively, which are suitable for gene expression. Secretory expression level of the precursors in methylotrophic yeast Pichia pastoris was quite high, 650 mg/L and 130 mg/L, respectively. In vivo biological assay showed that the two fast-acting insulins have full or nearly full biological activity. So both [B16Ala]insulin and [B26Ala]insulin can be well developed as fast-acting insulin for clinic use.     

Protein engineering of insulin: Two novel fast-acting insulins [B16Ala]insulin and [B26Ala]insulin

Insulin has been successfully used in clinic treatment of diabetes for more than 80 years. However, the clinic practice has shown that regular insulin preparation used in clinic exhibits several intrinsic problems that have existed for a long time. One of the major problems is that insulin has a potency of self-association when its concentration is higher than physiological concentration (10-8—10-10 mol/L)[1,2]. The concentration of the regular insulin is higher than 10-4 mol/L. At such a hi…     

B8Gly在胰岛素结构模体中的可能作用

在胰岛素结构模体ｎ１－Ｃｙｓ－Ｇｌｙ－Ｘ１０－Ｃｙｓ－ｎ２－Ｃｙｓ－Ｃｙｓ－Ｘ３－Ｃｙｓ－Ｘ８－Ｃｙｓ－ｎ３中,有７个绝对保守的氨基酸残基,只有位于Ｂ８位的是Ｇｌｙ。通过定点突变将其改变为Ａｌａ,得到「Ｂ８Ａｌａ」人胰岛素,其受体结合能力和体内生物活力分别为天然猪胰岛素的２．５％和１０％。「Ｂ８Ａｌａ」人胰岛素和重组人胰岛素的远紫外圆二色谱比较表明,「Ｂ８Ａｌａ」人胰岛素的α－螺旋的相对含量有一家     

B22 Glu Des-B30 Insulin： A Novel Monomeric Insulin

Studies on monomeric insulin with reduced self-association are important in the development of insulin pharmaceutical preparations with rapid hypoglycemic action on patients with diabetes. Here we report a novel monomeric insulin, B22 Glu des-B30 insulin, prepared from a single chain insulin precursor with B22 Arg mutated to Glu, which was expressed in Pichia pastoris and converted to B22 Glu des-B30 insulin by tryptic digestion. It still retains 50% of the in vivo biological activity of porcine insulin and does not form a dimer even at a concentration of 10 mg/ml, showing that B22 Glu plays a key role in reducing the self- association of the insulin molecule without greatly reducing its biological activity. This novel monomeric insulin might have potential applications in the clinic.     

Insulin analogs with B24 or B25 phenylalanine replaced by biphenylalanine

B24 and B25 phenylalanines （Phe） play important roles in insulin structure and function. Insulin analogs with B24 Phe or B25 Phe replaced by biphenylalanine （Bip） were prepared by enzymatic semisynthesis. The biological activities were determined by receptor binding assay and in vivo mouse convulsion assay. The results showed that B25 Bip insulin has 139% receptor binding activity and 50% in vivo biological activity, whereas B24 Bip insulin is inactive, when compared with native insulin, suggesting that B24 Phe is crucial for insulin activity. The structures in solution were studied by circular dichroism and fluoremetry, and our results suggested that the insulin analogs with low activities tend to be more tightly packed. The association properties were studied by size exclusion chromatography. The Bip.amide replacement of B24 Phe in deshexapeptide insulin or B25 Phe in despentapeptide insulin will cause the monomeric B24 Phe-amide deshexapeptide insulin or B25 Phe-amide despentapeptide insulin to associate and form dimers, whereas the mutations of B24 Phe in insulin will make insulin dimers dissociate into insulin monomers.     

胰岛素蛋白质工程：[B9Glu]人胰岛素

用基因定位突变方法将胰岛素Ｂ链第９位的Ｓｅｒ改为Ｇｌｕ。获得速效胰岛素─—［Ｂ９Ｇｌｕ］人胰岛素．它的受体结合能力和体内生物活力分别为猪胰岛素的２１％和４０％。     

胰岛素蛋白质工程：高活性［B10Asp］人胰岛素

用基因定位突变方法将胰岛素Ｂ链第１０位的Ｈｉｓ变为Ａｓｐ,获得高活力胰岛素──［Ｂ１０Ａｓｐ］人胰岛素。其受体结合能力和离体生物活力分别为猪胰岛素的２６２％和２３５％;体内生物活力也明显高于猪胰岛素;它的促细胞生长能力为猪胰岛素的１７４％。     

还原型胰岛素A、B链相互作用的初步研究

本文报道在chance所用“一步法”重组胰岛素的类似条件下,还原型A、B链相互作用研究的初步结果。在pH10.6对S—磺酸型A及B链加入1.2倍SH/SSO_3—的二巯基苏糖醇,在一小时内A、B链与DTT的混合物较之单独的A、B链与DTT的混合物,紫外差光谱显示295、245nm负差峰,峰值随时间增大;园二色性测定观察到混合链的α螺旋含量比单独的A、B链有所增加。这表明在A、B链的巯基氧化生成二硫链前,还原型A、B链间的相互作用导致Tyr残基逐渐内埋,肽链构象的调整使有序二级结构增加。根据此时还原程度的测定,讨论了DTT与S—磺酸型A、B链作巯基交换的可能机制,过多的还原试剂易破坏已正确配对的二硫键,也妨碍肽链构象的调整。     

Effects of citraconylation on enzymatic modification of human proinsulin using trypsin and carboxypeptidase B

Insulin is a polypeptide hormone which is produced by the β‐cell of pancreas and controls the blood glucose level in the human body. Enzymatic modification of human proinsulin using trypsin and carboxypeptidase B generally causes high accumulation of insulin derivatives, leading to more complicated purification processes. A simple method including citraconylation and decitraconylation in the enzymatic modification process was developed for the reduction of a major derivative, des‐threonine human insulin. Addition of 3.0 g citraconic anhydride per g protein into the reaction solution led to the citraconylation of lysine residues in human proinsulin and reduction of relative des‐threonine insulin content from 13.5 to 1.0%. After the enzymatic hydrolysis of the citraconylated proinsulin, 100% of lysine residues can be decitraconylated and restored by adjusting pH to 2–3 at 25 °C. Combination of hydrogen peroxide addition and citraconylation of proinsulin expressed in recombinant Escherichia coli remarkably improved the conversion yield of insulin from 52.7 to 77.7%. Consequently, citraconylation of lysine residues blocked the unexpected cleavage of human proinsulin by trypsin, minimized the formation of des‐threonine insulin and hence increased the production yield of active insulin. © 2009 American Institute of Chemical Engineers Biotechnol. Prog., 2009